MORF Morphic Holding, Inc. Net earnings per share growth this year

MORF (Morphic Holding Corp) - company brandmark

Morphic Holding, Inc. (MORF) is developing an oral therapy to combat intestinal inflammation. The relative EPS YoY dynamics on the GURU.Markets chart demonstrate a pivot driven by the implementation of AI-driven drug design and bioanalysis automation. Current growth is bolstered by news of a corporate acquisition, while the -10.80 level serves as a critical benchmark for assessing the company's operational expense management efficiency.

Earnings per share growth in current year: Morphic Therapeutic (MORF) for 07/04/2022 - 08/24/2024

Financial and market metric breakdowns for Morphic Holding, Inc. (MORF)

- share price and expert price forecast:
Price Morphic Therapeutic|MORF - Price Target Chart
- market capitalization data:
Market Valuation Morphic Holding Corp|MORF - Total Company Value
- company book value details:
Net Asset Value per Share Morphic|MORF - Company Book Value|Market Value to Book Value morphictx.com|MORF - Aggregate Company Assets
- debt and liquidity details:
Aggregate Debt to Equity Morphic Holding, Inc.|MORF - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital morphictx.com|MORF - Company Aggregate Debts|Debts to Net Assets Morphic Holding Corp|MORF - Company Long-Term Debts|Company Current Liabilities Morphic|Intermediate Coverage Ratio morphictx.com
- company profitability and valuation multiples indicators:
MORF - Net Profit|Expected Net Income Morphic Holding, Inc.|MORF - Price to Earnings Ratio|Projected Price to Earnings Ratio Morphic Holding Corp|MORF - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Morphic Holding Corp|MORF - Operating profit EBITDA|Earnings per share for the last 12 months Morphic|MORF - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months morphictx.com|MORF - Earnings per share growth in current year|Projected earnings per share growth rate for next year Morphic Holding, Inc.
- revenue and sales proceeds data:
MORF - Revenue and Sales Volume|Company Sales Forecast Morphic Therapeutic|MORF - Market Cap to Revenue|Forward Price to Sales Morphic Holding Corp
Fundamental valuation:MORF - Morphic Therapeutic
Product sample of morphictx.com

For Morphic Holding, Inc. (MORF), which develops oral alternatives to injectable gastrointestinal drugs, the year-over-year percentage change in EPS reflects the market consensus regarding net income growth rates. This indicator measures earnings per share dynamics by weighing biochemical development operating costs against final demand. A steady upward trend confirms the effectiveness of innovation monetization, although buying at peak values carries the risk of capital freeze.

Direct competitors

PHAT: Net earnings per one share growth for the current year|Earnings per share growth in current year Terns Pharmaceuticals Inc|Net earnings per share growth this year Ironwood Pharmaceuticals Inc (IRWD)|Earnings per share growth in current year Curanex Pharmaceuticals Inc (CURX)|IMRN - Earnings per share growth rate in current year|Earnings per share growth in current year Evoke Pharma EVOK|Earnings per share increase in current year ENTO|RDHL - Earnings per share growth in current year|Earnings per share trend in current year PALI|JAGX: Earnings growth in current year|bioratherapeutics.com - Earnings per share increase in current year